Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: A randomized clinical trial

IMpact of pocKet rEvision on the rate of InfecTion and other CompLications in patients rEquiring pocket mAnipulation for generator replacement and/or lead replacement or revisioN (MAKE IT CLEAN): A prospective randomized study

“…Bleeding rates from a recent meta-analysis (28) varied from 2.2% in patients with no anti-platelet or anticoagulant therapy to 14.6% in patients on heparin bridging therapy with a mean of 4.6%. Odds of bleeding increased with dual anti-platelet therapy (28,29) or heparin bridging (30) but not with continued anticoagulation (31,32). In our study, nearly 36% of the patients were on Coumadin with 7.5% of patient on dual anti-platelet therapy.…”

Management of Periprocedural Anticoagulation

“…These include pacemaker and implantable cardioverter-defibrillator implantation, dental extraction, and cataract surgery (5)(6)(7)(8)(9). The ability to perform procedures at lower risk of bleeding without interruption of oral AC reduces the need for parenteral AC and the additional risk of bleeding.…”

Anticoagulation Management in the Perioperative Phase of Implantable Cardioverter Defibrillator Implantation

“…31, 36 In contrast to the retrospective studies, 14-16,32-35 a prospective study showed that development of pocket hematoma after implanting/replacing a pacemaker or ICD was observed in 7.8% of patients treated with heparin bridging, and in 8.0% of those with oral anticoagulation who maintained an INR of 2±0.3. 31 In another prospective study, there was a trend toward reduced complications in patients with warfarin continuation, 36 but the results were not statistically significant, possibly due to the small number of patients (n=7) randomized to heparin bridging.…”